Enlightened Opinion

Partners4Access > Enlightened Opinion

Future-proofing 2019 plans: P4A’s 6 Orphan Drug, Cell & Gene Therapy trends to watch out for


2019 is expected to a strong year for the orphan drug industry with an expected 10% surge in sales growth. Contributing to this growth will be new treatment launches particularly from cell and gene therapies. As these novel therapies are geared towards commercialization, the industry is witnessing a change in approach by manufacturers, regulators and […]

Read More

Webinar 2: U.S. lessons learnt from Kymriah & Luxturna

In the second of three webinars, P4A is focussing on the US environment for gene therapies. Single application cell and gene therapies in the US face health insurance challenges driven by a short-term focus, disconnection between price reporting and outcomes value, and complex distribution models…

Read More


In our mission to understand and influence the debate on Orphan Drugs, P4A will be closely following industry and scientific conferences including attending some of them.

All Rights Reserved ©   Privacy   Partners 4 Access 2018